AI assistant
Lasa Supergenerics Limited Capital/Financing Update 2021
61953_rns_2021-06-09_3999054c-18af-410d-af14-6d085835a4d7.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Ref. No.: LASA/SE/21-22/12
Wednesday June 09, 2021
| To, | To, |
|---|---|
| CorporateServicesDepartment | Corporate Services Department |
| BSE Limited | NationalStockExchangeofIndiaLimited |
| PhirozeJeejeebhoyTowers, | "ExchangePlaza",PlotNo.C/1, |
| DalalStreet, | GBlockBandra-KurlaComplex, |
| Mumbai –400001. | Bandra(E),Mumbai–400051. |
| BSECODE–540702 | NSE CODE: LASA |
Dear Sir/Madam,
Subject: Media Release
Attached is the copy of Press Release titled "LASA launches new product – Oxyclozanide Creating new Capacity as a brown field expansion" issued by the company.
You are requested to take the same on your record.
THANKING YOU YOURS SINCERELY FOR LASA SUPERGENERICS LIMITED
NIDHI KULSHRESHTHA COMPANY SECRETARY AND COMPLIANCE OFFICER
Media Release
LASA launches new product - Oxyclozanide
Creating new Capacity as a brown field expansion
Company plansto target both domestic as well as export markets
Production to commence from August 2021
Mumbai, June 9, 2021: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading players in the manufacturing of Veterinary and Human APIs in India through its catalyst chemistry expertise and fully backward integrated unit, has added another product - Oxyclozanide to its portfolio of products.
Oxyclozanide is an anthelmintic. It is used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle (especially buffalos in farm), sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit. The total capacity would be 250 MT and The Company is committed to funding the required Capex through internal accruals. The production would start from August 2021.
The product is in huge demand and the management is confident of having a strong order book from the time production commences. The Company already has export approvals for several regions. Oxyclozanide would also be exported to these regions.
Lasa Supergenerics LimitedCIN: L24233MH2016PLC274202
Management Comments:
Commenting on the recent development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:
"We are very pleased to inform that the Company has added another interesting product to its portfolio. Oxyclozanide is an anthelmintic. It has a huge opportunity both in domestic as well export markets. The additional capacity is being put within the existing facility at Chiplun, Maharashtra. This, like other products, is also a difficult product to manufacture and hence there are not many players manufacturing it. Also, it is a product of regular consumption within the veterinary space. Since we already possess various certificates to export to different regions, we would be targeting both domestic and export markets. We are very excited about the launch of Oxyclozanide as it fit our product selection criteria and we are confident of grabbing a significant market share. Besides this we have plan to come up with one more product details of which shall be shared shortly. The Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.
I would like to thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."
About Lasa Supergenerics Limited:
Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specializes in 'catalyst chemistry' and manufactures anthelmintic / veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.
For more details please visit: www.lasalabs.com For any Investor Relations query, please contact:
Mr Hitesh Wadhwani Lasa Supergenerics Limited Email: [email protected]
Note: Certain statements in this document may be forward-looking statements. Such forwardlooking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.